TrialBlood2025

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation.

Anita Kumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.